California Public Employees Retirement System Has $6.11 Million Position in Glaukos Co. (NYSE:GKOS)

California Public Employees Retirement System raised its position in Glaukos Co. (NYSE:GKOS - Free Report) by 10.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,804 shares of the medical instruments supplier's stock after purchasing an additional 7,107 shares during the quarter. California Public Employees Retirement System owned about 0.16% of Glaukos worth $6,105,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in GKOS. Invesco Ltd. increased its stake in shares of Glaukos by 45.5% during the third quarter. Invesco Ltd. now owns 1,450,033 shares of the medical instruments supplier's stock valued at $109,115,000 after acquiring an additional 453,756 shares during the period. Rhenman & Partners Asset Management AB increased its stake in shares of Glaukos by 236.8% during the third quarter. Rhenman & Partners Asset Management AB now owns 320,000 shares of the medical instruments supplier's stock valued at $24,080,000 after acquiring an additional 225,000 shares during the period. Fred Alger Management LLC increased its stake in shares of Glaukos by 9.2% during the third quarter. Fred Alger Management LLC now owns 1,780,690 shares of the medical instruments supplier's stock valued at $133,997,000 after acquiring an additional 150,102 shares during the period. Lisanti Capital Growth LLC acquired a new position in shares of Glaukos during the third quarter valued at approximately $6,367,000. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Glaukos by 3,894.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 72,978 shares of the medical instruments supplier's stock valued at $5,801,000 after acquiring an additional 71,151 shares during the period. Institutional investors and hedge funds own 99.04% of the company's stock.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 140,245 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $92.14, for a total transaction of $12,922,174.30. Following the completion of the transaction, the chief operating officer now owns 98,388 shares of the company's stock, valued at approximately $9,065,470.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Glaukos news, COO Joseph E. Gilliam sold 140,245 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $92.14, for a total transaction of $12,922,174.30. Following the completion of the transaction, the chief operating officer now owns 98,388 shares of the company's stock, valued at approximately $9,065,470.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Alex R. Thurman sold 474 shares of the business's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $90.37, for a total transaction of $42,835.38. Following the transaction, the chief financial officer now directly owns 54,916 shares of the company's stock, valued at approximately $4,962,758.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 232,881 shares of company stock valued at $21,965,491. Insiders own 6.40% of the company's stock.

Glaukos Stock Up 1.4 %

Shares of GKOS stock traded up $1.48 on Friday, hitting $106.51. The company's stock had a trading volume of 507,497 shares, compared to its average volume of 497,055. The company has a debt-to-equity ratio of 0.78, a current ratio of 5.38 and a quick ratio of 4.78. Glaukos Co. has a fifty-two week low of $49.19 and a fifty-two week high of $108.22. The firm's fifty day moving average price is $93.33 and its 200-day moving average price is $83.07. The stock has a market capitalization of $5.35 billion, a price-to-earnings ratio of -36.98 and a beta of 1.08.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.12). Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The business had revenue of $85.60 million during the quarter, compared to analyst estimates of $79.60 million. During the same period in the previous year, the firm posted ($0.59) EPS. The firm's revenue for the quarter was up 15.8% on a year-over-year basis. Research analysts anticipate that Glaukos Co. will post -2.2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GKOS. BTIG Research raised their target price on shares of Glaukos from $107.00 to $112.00 and gave the stock a "buy" rating in a report on Thursday. StockNews.com cut shares of Glaukos from a "hold" rating to a "sell" rating in a report on Tuesday, February 27th. Wells Fargo & Company raised their target price on shares of Glaukos from $103.00 to $110.00 and gave the stock an "overweight" rating in a report on Thursday. Mizuho raised their target price on shares of Glaukos from $85.00 to $100.00 and gave the stock a "neutral" rating in a report on Thursday, April 11th. Finally, Stifel Nicolaus restated a "buy" rating and set a $110.00 target price on shares of Glaukos in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $107.00.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.